Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan
Дата публикации: 26-06-2026 08:06:00

New indication concerns the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
2EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
3EMA Recommends Extension of Therapeutic Indications for Encorafenib0503-07-2026
4FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC5724-06-2026
5Empresas.- Trastuzumab deruxtecán recibe la aprobación en la UE para tumor agnóstico en pacientes con tumores sólidos0708-07-2026
6Enhertu превзошел стандартную первую линию терапии при HER2-мутантном раке легкого в исследовании III фазы017.1418-08-2026
7FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC013.1329-07-2026
8FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer5508-07-2026
9Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer01028-07-2026
10New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer5702-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.esmo.org.